LQDA

54.4053.93%
RS

Rajeev Saggar

Chief Medical Officer

Dr. Rajeev Saggar, MD, QME, is Doctor of Internal Medicine of Pulmonary of California Medical Evaluators, Inc. Dr. Saggar serves as Chief Medical Officer at Liquidia Corporation since July 18, 2022. He has experience as a practicing pulmonologist and has authored more than 60 peer- reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD). Dr. Saggar has previously served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix since january 2017 until December 2019 and the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix since July 2015 until December 2019. In his role at Banner Medical Center, he served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. Just prior to joining Liquidia, Dr. Saggar served as Vice President of Clinical Development at Theravance Biopharma since January 2020 until July 2022, with oversight of all phases of clinical development across respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD and COVID-19. He served as General Manager of Evolung, Limited Liability Company(a subsidiary of United Therapeutics) from July 2013 to April 2014. He served as the Associate Director of Lung Transplant and Medical Director of Advanced Lung Disease at Norton Thoracic Institute from July 2011 to June 2013. Dr. Saggar received a M.D. degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.

Positions